EHMT2 and cardiac hypertrophy: A histone methyltransferase G9a, known to mono- and di-methylate H3K9, is required to promote pathological cardiac hypertrophy, and the treatment with its specific inhibitor BIX-01294 has improved cardiac dysfunction in response to pressure overload [53].